×

Home Top Podcaster Networks By Language By Country By Category About Us Contact Us Faqs Features News & Blogs Privacy Policy Terms Of Use

☰

Search

Home > REBEL Cast > REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies


	Podcast:		REBEL Cast
	Episode:		REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies
	Category:		Science & Medicine
	Duration:		00:11:52
	Publish Date:		2019-04-03 07:00:13
	Description:		Take Home Points on Non-Inferiority Studies Non-inferiority studies should be done when a new treatment (or diagnostic modality) requires less resources (cost or time), is easier for the patient or has a lower side-effect profile. Non-inferiority study design largely negates the protections against bias added by blinding and randomization. Non-inferiority studies can be used to manipulate clinicians when a superiority study would be more appropriate. REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies Click here for Direct Download of Podcast Links: REBEL EM: Omadacycline, the NEJM and Non-Inferiority Studies First 10 EM: Andexanet Alfa: More Garbage Science in the New England Journal of Medicine EM Nerd: The Case of the Scientific Ruse References: Stets R et al. Omadacycline for Community-Acquired Bacterial Pneumonia. NEJM 2019; 380(6): 511-27. PMID: 30726692 O’Riordan W et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. NEJM 2019; 380(6): 528-38. PMID: 30726689 Lundh A et al. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med 2018; 44(10): 1603-12. PMID: 30132025 Post Peer Reviewed By: Salim R. Rezaie, MD (Twitter: @srrezaie) The post REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies appeared first on REBEL EM - Emergency Medicine Blog.
	Total Play:		0